 |
|
Meta-analysis of Genetic Studies in Ischemic Stroke
Thirty-two Genes Involving Approximately 18 000 Cases and 58 000 Controls
Juan P. Casas, MD;
Aroon D. Hingorani, MRCP, PhD;
Leonelo E. Bautista, MD, MPH, DrPh;
Pankaj Sharma, MD, PhD
Arch Neurol. 2004;61:1652-1661.
ABSTRACT
| |
Ischemic stroke is thought to have a polygenic basis, but identification of stroke susceptibility genes and quantification of associated risks have been hampered by conflicting results from underpowered case-control studies. We performed a meta-analysis of all candidate gene association studies in ischemic stroke. Electronic databases were searched up until January 2003 for all case-control and nested case–control studies in English-language journals relating to the investigation of any candidate gene for ischemic stroke in humans. Cases were required to have neuroimaging evidence of the diagnosis. To maintain genetic homogeneity, only studies in white adults were included. Studies that evaluated quantitative traits or intermediate phenotypes were excluded. Data from 120 case-control studies were included. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) from random- and fixed-effects models were calculated. Of 32 genes studied, 15 polymorphisms were identified for which at least 3 studies had been conducted. Statistically significant associations with ischemic stroke were identified for factor V Leiden Arg506Gln (OR, 1.33; 95% CI, 1.12-1.58), methylenetetrahydrofolate reductase C677T (OR, 1.24; 95% CI, 1.08-1.42), prothrombin G20210A (OR, 1.44; 95% CI, 1.11-1.86), and angiotensin-converting enzyme insertion/deletion (OR, 1.21; 95% CI, 1.08-1.35). These were also the most investigated candidate genes, including 4588, 3387, 3028, and 2990 cases, respectively. No statistically significant association with ischemic stroke was detected for the 3 next most investigated genes (factor XIII, apolipoprotein E, and human platelet antigen type 1). There is a genetic component to common stroke. No single gene with major effect was identified; rather, common variants in several genes, each exerting a modest effect, contribute to the risk of stroke. These findings have important implications for the design of future genetic studies and for predictive genetic testing for stroke and other multifactorial diseases.
INTRODUCTION
According to the World Health Organization, stroke is the third most common cause of death in developed countries.1 In the United States there are more than 700 000 incident strokes annually and 4.4 million stroke survivors every year.2 The economic burden of stroke has been estimated to be $51.2 billion annually.3 Because treatments for stroke are limited, the best approach to reducing the burden of disease is primary prevention through modification of acquired risk factors (diabetes mellitus, smoking, high blood pressure, and atrial fibrillation),4 particularly in persons at elevated risk. Stroke cases cluster in families,5 and there is a nearly 5-fold difference in stroke prevalence among monozygotic vs dizygotic twins.6 Epidemiologic studies suggest a polygenic basis for stroke,7-9 and the favored model for the pathogenesis of stroke is an interaction between genetic and acquired risk factors.10
In theory, identification of stroke susceptibility genes might enhance prediction of disease risk. However, the lack of reproducibility of genetic case-control studies has led to uncertainty about the nature and number of genes contributing to stroke risk. There is concern, on one hand, that positive associations might be spurious and, on the other hand, that the negative findings from some studies might be a consequence of inadequate statistical power.
With a case-control design, sample sizes of thousands are required to have adequate power to detect genes of small to moderate effect whose allele frequencies range from 5% to 10%. Few individual studies conducted to date have been of this size. By using all available published data to increase statistical power, meta-analysis might allow plausible candidate genes to be excluded, causative genes to be identified with reliability, and genetic risks to be quantified with more precision. Therefore, we undertook a comprehensive meta-analysis of all genetic case-control studies in ischemic stroke to date.
METHODS
DATA SOURCES
Electronic databases (MEDLINE, EMBASE, and BIDS [Bath Information and Data Services]) were searched up until January 2003 for all case-control studies evaluating any candidate gene and stroke in humans. Letters and abstracts were included in the meta-analysis. The Medical Subject Headings terms and text words used for the search were cerebrovascular disease, stroke, brain infarction, and cerebral ischemia in combination with genetic, polymorphism(s), mutation, genotype, or genes. The search results were limited to human. All languages were searched initially, but only English-language articles were selected. The references of all computer-identified publications were searched for any additional studies, and the MEDLINE option related articles was used for all the relevant articles. In addition, a search to identify previous genetic meta-analyses in stroke was also performed.
STUDY SELECTION
Studies were selected if neuroimaging (magnetic resonance imaging or computed tomography) had been used to confirm the diagnosis of ischemic stroke, and, to maintain homogeneity of genetic background, only studies of white patients were included. Studies were excluded if (1) the patients were children (aged <18 years), (2) quantitative traits or intermediate phenotypes were being investigated, or (3) genotype frequency was not reported. For duplicate publications, the smaller data set was discarded.
DATA EXTRACTION
The primary search generated 155 potentially relevant articles, of which 120 met the inclusion criteria. Data for analysis were extracted independently and entered into separate databases by 2 of us (J.P.C. and P.S.). The results were compared, and disagreements were resolved by consensus.
STATISTICAL ANALYSIS
Data were analyzed using software for preparing and maintaining Cochrane reviews (Review Manager, version 4.1; Cochrane Collaboration, Syracuse, NY) and statistical analysis software (Stata 8.0; Stata Corp, College Station, Tex). For each genetic marker (polymorphism) for which data were available for at least 3 studies, a meta-analysis was carried out. For each gene variant, a pooled odds ratio (OR) was calculated using fixed- and random-effects models, along with the 95% confidence interval (CI) to measure the strength ofthe genetic association. Fixed-effects summary ORs were calculated using the Mantel-Haenszel method,11-12 and the DerSimonian and Laird method was used to calculate random-effects summary ORs.13
Tests for heterogeneity were performed for each meta-analysis (with significance set at P < .05).14 For assessment of publication bias, we used the funnel plot and the Egger regression asymmetry test.15 In addition, the effect of individual studies on the summary OR was evaluated by reestimating and plotting the summary OR in the absence of each study.
The proportion of stroke cases in the population that could be attributed to a particular genetic variant (population-attributable risk [PAR]) was estimated as follows:
PAR = 100 x [Prevalence (OR – 1)/Prevalence (OR – 1) + 1].
For this calculation, we used the fixed-effects model, and we estimated the prevalence of exposure as the genotype frequency among control subjects.
DATA SYNTHESIS
One hundred twenty candidate gene case-control studies in which the presence or absence of stroke was analyzed in a dichotomous manner were identified. In total, 51 polymorphisms in 32 genes were identified. Of these, data were available from at least 3 studies for 15 polymorphisms in 13 genes. For another 6 polymorphisms, 2 studies per genetic marker were identified, and, in the case of 30 polymorphisms, only 1 study per genetic marker was identified that met the selection criteria. From the 15 polymorphisms analyzed in detail (representing 18 123 cases and 57 579 controls), the mean number of studies per candidate gene was 9 (95% CI, 4.3-12.8). Eight (53%) of the 15 meta-analyses had more than 1000 cases, and 7 (47%) had at least 1 study with a total sample size greater than 1000 (Table).
|
|
|
|
Table. Candidate Genes and Ischemic Stroke
|
|
|
The Table shows the genotypic ORs for the 15 polymorphisms evaluated. Of those candidate genes with statistically significant associations, the summary ORs varied from 1.21 (95% CI, 1.08-1.35) for angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism to 1.88 (95% CI, 1.28-2.76) for the polymorphism of the glycoprotein Ib- (GPIBA) Kozak sequence (Table).
The factor V Leiden mutation has been by far the most investigated, with 26 studies16-41 that included 4588 cases and 13 798 controls. Carriers of the factor V Gln506 allele were 1.33 times more likely to develop stroke (95% CI, 1.12-1.58; P = .001) (Table and Figure 1). However, significant interstudy OR heterogeneity was observed ( 2 = 39.78; P for heterogeneity [PHet] = .03). A sensitivity analysis revealed that the study by Margaglione et al30 was mainly responsible for the heterogeneity observed. After excluding this study from the analysis, the heterogeneity was no longer significant (2 = 18.87; PHet = .76), but the OR was attenuated and of marginal significance (OR, 1.18; 95% CI, 0.98-1.42; P = .08). Nevertheless, a random-effects model that takes into account the intrastudy and interstudy variability resulted in a similar overall estimate (OR, 1.31; 95% CI, 1.02-1.68; P = .03), although the 95% CIs are wide, leading to some uncertainty about the size of the effect. The distribution of the OR in relation to its standard deviation in the funnel plot was symmetrical, and the Egger test result was not significant (P = .89), suggesting a low probability of publication bias.
|
|
|
|
Figure 1. Results of published studies of the association between the factor V Leiden mutation and ischemic stroke. Odds ratios for the outcome compared carriers of the Gln506 allele vs wild type (Arg/Arg). CI indicates confidence interval. The size of the box is porportional to the weight of the study.
|
|
|
A total of 22 studies20, 28-30,34, 38, 40, 42-56 (3387 cases and 4597 controls) were identified that evaluated the polymorphism in the gene encoding methylenetetrahydrofolate reductase where cytosine is replaced by thymidine at base position 677 of the gene (MTHRF C677T). A summary OR, under the fixed-effects model, of 1.24 (95% CI, 1.08-1.42; P = .002) was observed for individuals homozygous for the T allele compared with C allele carriers (C/T plus C/C) (Figure 2). The funnel plot distribution was symmetrical and the Egger test was not significant (P = .08), indicating a low probability of publication bias. No significant interstudy heterogeneity was observed (2 = 25.64; PHet = .22), and no individual study had an undue effect on the summary OR.
|
|
|
|
Figure 2. Results of published studies of the association between the methylenetetrahydrofolate reductase C677T polymorphism and ischemic stroke. Odds ratios for the outcome compared individuals homozygous for the T allele (T/T) with those heterozygous individuals (C/T) plus wild type (C/C). CI indicates confidence interval. The size of the box is porportional to the weight of the study.
|
|
|
The prothrombin G20210A mutation was evaluated in 19 studies,17, 20, 22-23,26, 28-30,32, 34, 38, 40, 57-63 with a total of 3028 cases and 7131 controls. The summary OR under a fixed-effects model showed that carriers of the mutation were 1.44 times more likely to develop stroke (95% CI, 1.11-1.86; P = .006) (Figure 3). No significant interstudy heterogeneity was observed (2 = 10.59; PHet = .91). The distribution of theORs from individual studies in relation to their respective standard deviations (funnel plot) was symmetrical, and the Egger test result suggested a low probability of publication bias (P = .13). Again, no individual study had an undue effect on the summary OR.
|
|
|
|
Figure 3. Results of published studies of the association between the prothrombin G20210A polymorphism and ischemic stroke. Odds ratios for the outcome compared carriers of the A allele with those with wild type (G/G). CI indicates confidence interval. The size of the box is porportional to the weight of the study.
|
|
|
The ACE I/D polymorphism was evaluated in 11 studies38, 64-73 (2990 cases and 11 305 controls), and a summary OR of 1.21 (95% CI, 1.08-1.35; P<.001), under a fixed-effects model, was observed for individuals homozygous for the D allele compared with heterozygous (D/I) and homozygous (I/I) individuals combined (Figure 4). The funnel plot showed a symmetrical distribution of the OR in relation to its standard deviation, and the Egger test result did not suggest the presence of publication bias (P = .22). No significant interstudy heterogeneity was observed (2 = 9.71; PHet = .47), and as for MTHFR C677T and prothrombin G20210A, no individual study had an undue effect on the summary OR.
|
|
|
|
Figure 4. Results of published studies of the association between the ACE I/D polymorphism and ischemic stroke. Odds ratios for the outcome compared individuals homozygous for the D allele with those with the heterozygous (D/I) plus wild type (I/I). CI indicates confidence interval. The size of the box is porportional to the weight of the study.
|
|
|
The PARs for the 4 positive and most investigated candidates—ACE I/D, MTHFR C677T, factor V Leiden, and prothrombin G20210A—following the models of inheritance shown in the Table were 4.54%, 3.31%, 2.16%, and 1.30%, respectively.
Other genetic markers associated with an increase in the risk of stroke but for which the data set was much smaller were glycoprotein Ib- Thr Met or human platelet antigen (HPA) type 2 (HPA2) (4 studies88, 91, 102, 104 with 564 cases; OR, 1.55; 95% CI, 1.14-2.11; P = .006), and plasminogen activator inhibitor 1 (PAI1) promoter 4G/5G I/D (4 studies74, 99-101 with 842 cases; OR, 1.47; 95% CI, 1.13-1.92; P = .004), with no evidence for heterogeneity in either meta-analysis. Meta-analysis of studies of GPIBA Kozak sequence was positive (3 studies102, 107-108 with 350 cases; OR, 1.88; 95% CI, 1.28-2.76; P = .001) (Table), but studies were highly heterogeneous.
Of the remaining 8 polymorphisms studied, no significant associations were observed for 3 genes with large data sets: apolipoprotein E  4, 3, 2 (10 studies50, 56, 80-87 and 1805 cases; OR, 0.96; 95% CI, 0.84-1.11; P = .60) (Figure 5), factor XIII ValLeu (6 studies74-79 with 2166 cases; OR, 0.97; 95% CI, 0.75-1.25; P = .80) (Figure 6), and glycoprotein IIIa Leu33Pro or HPA1 (9 studies23, 88-95 with 1467 cases; OR, 1.11; 95% CI, 0.95-1.28; P = .20) (Figure 7) polymorphisms (Table). Five of the remaining negative meta-analyses each had a small sample size (endothelial nitric oxide synthase [eNOS] Glu298Asp, 1086 cases; GPIBA variable number tandem repeat [VNTR], 816 cases; glycoprotein IIb IleSer, 770 cases; factor VII A1/A2, 545 cases; and lipoprotein lipase [LPL] Asn291Ser, 452 cases). Overall, these 8 negative meta-analyses included fewer cases than the 7 meta-analyses in which significant associations were detected (mean number of cases: 1138 [95% CI, 621-1655] vs 2250 [95% CI, 723-3776]; P value for difference = .046).
|
|
|
|
Figure 6. Results of published studies of the association between the factor XIII polymorphism and ischemic stroke. Odds ratios for the outcome compared individuals homozygous for the Leu34 allele (Leu/Leu) with those with the heterozygous (Val/Leu) plus wild type (Val/Val). CI indicates confidence interval. The size of the box is porportional to the weight of the study.
|
|
|
|
|
|
|
Figure 7. Results of published studies of the association between the glycoprotein IIIa polymorphism and ischemic stroke. Odds ratios for the outcome compared individuals homozygous for the Pro allele with those with the heterozygous (Leu/Pro) plus wild type (Leu/Leu). CI indicates confidence interval. The size of the box is porportional to the weight of the study.
|
|
|
COMMENT
In this comprehensive meta-analysis, 7 (47%) of the 15 candidate polymorphisms analyzed significantly increased the risk of stroke among individuals of European ancestry. In 4 of these meta-analyses (ACE I/D, factor V Leiden, MTHFR C677T, and prothrombin G20210A), the mean number of cases included per gene was more than 3000, allowing more precise estimates to be made of the effect of these genes than from any single study. However, the individual risk provided by any one of these candidate genes was moderate (OR, 1.21-1.44). This is in agreement with previous studies112-114 in other complex diseases, such as ischemic heart disease.
Most candidate genes assessed in stroke thus far have been evaluated initially for their potential role in ischemic heart disease. Therefore, up to now, most genetic studies (73% of the meta-analyses described in this article) have focused on genes involved in thrombosis and coagulation, whereas genes regulating other well-established risk factors for stroke (eg, hypertension, diabetes mellitus, and hyperlipidemia) have received relatively limited attention. Thus, it is possible that several additional genes with similar risks may exist but have yet to be evaluated.
For the genes with positive associations and large data sets, mechanistic studies have indicated the processes by which risk alleles might alter the expression or activity of the encoded protein and contribute to disease pathogenesis. The factor V Leiden mutation causes activated protein C resistance.115 Activated protein C limits clot formation by proteolytic inactivation of factors Va and VIIIa, and the single point mutation in the gene for factor V (1691GA) studied predicts replacement of arginine by glycine at position 506 in the activated protein C cleavage site. After activation, the mutated factor V is less efficiently degraded by activated protein C than normal factor V, resulting in increased thrombin generation and a hypercoagulable state, which may explain the increased risk of stroke in carriers of this mutation observed in this study.116 A sequence variation in the 3'-untranslated region of the prothrombin gene (G20210A), which alters messenger RNA stability, is associated with elevated prothrombin levels117-118 and thrombin formation117 and may similarly lead to a procoagulant state.
Plasma and intracellular levels of ACE have been shown to be partly determined by the presence of the ACE I/D polymorphism in healthy individuals and in patients with stroke.119-120 Individuals homozygous for the D allele have a 56% increase in ACE activity compared with I allele homozygotes.121 Angiotensin-converting enzyme converts angiotensin I to angiotensin II, which is known to be involved in vascular hypertrophy, vasoconstriction, and atherosclerotic processes.122 Also, ACE is responsible for degradation of bradykinin, a vasoactive peptide that has been suggested to stimulate vasodilator nitric oxide production.122
Long-term differences of 5 µmol/L in the serum concentration of homocysteine are associated with a 59% increase in the risk of stroke.112 The C677T mutation in the MTHFR gene, which encodes an amino acid substitution (A222V), renders the enzyme thermolabile and reduces metabolism of homocysteine.123 A recent meta-analysis124 in coronary heart disease showed that, on average, patients homozygous for the T allele had a 2.2-µmol/L higher serum level of homocysteine than patients with the C/C genotype and have a 1.16-fold increased risk of developing coronary heart disease. Findings from the present meta-analysis suggest that this variant is associated with a similar increase in the risk of stroke.
Taken together, the evidence from these meta-analyses, the molecular studies, and the effects of these genes on other cardiovascular phenotypes supports a role for variants in factor V, prothrombin, MTHFR, and ACE genes in susceptibility to stroke, but verification will be required from larger studies.
The PARs for these polymorphisms ranged from 1.30% for prothrombin G20210A to 4.54% for ACE I/D, values that are far lower than those reported for well-established acquired risk factors for ischemic stroke (eg, hypertension, smoking, and diabetes mellitus).4 This low level of PAR is not surprising, because the genetic contribution of any single gene toward a complex disease is unlikely to act in a simple mendelian fashion but rather with epistatic (gene-gene or gene-environmental interaction) effects. Nevertheless, given the high incidence of stroke, if these estimates are correct, they suggest that variants in 4 common genes may contribute to 9000 to 32 000 strokes in the United States each year.
Meta-analyses of 3 gene variants—apolipoprotein E 4, 3, 2 (1805 cases), factor XIII ValLeu (2166 cases), and glycoprotein IIIa Leu33Pro (1467 cases)—has so far failed to provide evidence of increased stroke susceptibility. The sample sizes of these meta-analyses allowed exclusion of ORs as low as 1.14, 1.20, and 1.35, respectively, with 80% power at P = .05. It seems unlikely, therefore, that carriers of the apolipoprotein E 4 allele, which affects serum cholesterol, and which has been associated with a moderate increase in the risk of coronary heart disease,114 are at a substantially higher risk of stroke. Of the remaining 8 meta-analyses with relatively small data sets, 3 (PAI1 4G/5G [842 cases], HPA2 ThrMet [564 cases], and GPIBA Kozak sequence [350 cases]) identified significant associations. However, additional larger studies are required to confirm or refute these findings.
The interpretation of any meta-analysis must be made within the context of its limitations, including study selection, publication bias, and variability in the methodological quality of the included studies. The present meta-analyses were restricted to studies published in the English language, but our overall computer search identified only a few non-English studies.125-129 Although publication bias cannot be excluded, this is an unlikely explanation for our findings. Many of the individual studies included in our meta-analysis were not statistically significant and were interpreted by their authors as negative studies. In addition, the Egger asymmetry test and the funnel plot showed no substantialevidence of publication bias in the 7 largest (N>3000) meta-analyses (ACE I/D; factor V Leiden; MTHFR C677T; prothrombin G20210A; apolipoprotein E 4, 3, 2; factor XIII ValLeu; and glycoprotein IIIa Leu33Pro). Moreover, rigorous selection criteria (neuroimaging and ethnic homogeneity) enriched the meta-analyses for studies with comparable selection of participants. Thus, lack of specificity, by the inclusion of individuals with hemorrhagic stroke or those with a clinical diagnosis of stroke but without neuroimaging evidence, was avoided.
Although it is not possible to exclude the future identification of 1 or more genes with a more substantial effect on stroke risk, our findings suggest that several genes, each with a small to moderate effect, are likely to act individually, together, or in combination with environmental determinants to cause stroke. One implication of these findings is that predictive genetic tests that use any single variant are unlikely individually to have much value. However, tests that combine genotyping for 1 or more risk alleles and that integrate the results with established risk prediction tools based on acquired risk factors (eg, the Framingham risk equation) may have greater utility.130 Another important consequence for future research is that very large case-control studies with several thousand participants will be required to detect new risk alleles with small to moderate effects of the size identified in our review, and to confirm or refute our findings. Because recruitment of data sets of this size may be difficult for a single medical center, a complementary approach has been suggested that involves the recruitment and genotyping of fewer patients and controls from many centers according to uniform criteria and submission of the data (whether nominally positive or negative) to a common Web-based repository for online, continuously updated and cumulative meta-analysis,131 which reduces the potential for publication bias.
In summary, our study confirms the existence of a genetic cause for common stroke but with no single common "stroke gene" exerting a major effect. Instead, several stroke susceptibility alleles are likely to act individually, together, or in combination with environmental determinants to cause stroke.
AUTHOR INFORMATION
Correspondence: Pankaj Sharma, MD, PhD, Hammersmith Hospitals Acute Stroke Unit, Imperial College, Fulham Palace Road, London W6 8RF, England (psharma{at}hgmp.mrc.ac.uk).
Accepted for Publication: March 23, 2004.
Author Contributions: Study concept and design: Casas, Hingorani, and Sharma. Acquisition of data: Casas, Hingorani, and Sharma. Analysis and interpretation of data: Casas, Hingorani, Bautista, and Sharma. Drafting of the manuscript: Casas, Hingorani, Bautista, and Sharma. Critical revision of the manuscript for important intellectual content: Hingorani, Bautista, and Sharma. Statistical analysis: Casas, Hingorani, Bautista, and Sharma. Obtained funding: Hingorani and Sharma. Administrative, technical, and material support: Hingorani and Sharma. Study supervision: Sharma.
Funding/Support: Dr Hingorani holds a Senior Fellowship from the British Heart Foundation, London.
Author Affiliations: Centre for Clinical Pharmacology, British Heart Foundation Laboratories at University College London, London, England (Drs Casas and Hingorani); Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, Md (Dr Bautista); and Hammersmith Hospitals Acute Stroke Unit and Department of Cellular and Molecular Neuroscience, Imperial College, University of London (Dr Sharma).
REFERENCES
| |
1. World Health Organization. The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: World Health Organization; 2002.
2. National Heart, Lung, and Blood Institute. Morbidity & Mortality: 2002 Chartbook on Cardiovascular, Lung, and Blood Diseases. Bethesda, Md: National Institutes of Health; 2002.
3. American Heart Association. Economic cost of cardiovascular diseases. Available at: http://www.americanheart.org/statistics/10econom.html. Accessed June 15, 2003.
4. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation. 2001;103:163-182.
FREE FULL TEXT
5. Hrubec Z, Robinette CD. The study of human twins in medical research. N Engl J Med. 1984;310:435-441.
ISI
| PUBMED
6. Brass LM, Isaacsohn JL, Merikangas KR, et al. A study of twins and stroke. Stroke. 1992;23:221-223.
FREE FULL TEXT
7. Rubattu S, Volpe M, Kreutz R, Ganten U, Ganten D, Lindpaintner K. Chromosomal mapping of quantitative trait loci contributing to stroke in a rat model of complex human disease. Nat Genet. 1996;13:429-434.
FULL TEXT
|
ISI
| PUBMED
8. Kiely DK, Wolf PA, Cupples LA, et al. Familial aggregation of stroke: the Framingham Study. Stroke. 1993;24:1366-1371.
FREE FULL TEXT
9. Sharma P. Genes for ischaemic stroke: strategies for their detection. J Hypertens. 1996;14:277-285.
FULL TEXT
|
ISI
| PUBMED
10. Liao D, Myers R, Hunt S, et al. Familial history of stroke and stroke risk: the Family Heart Study. Stroke. 1997;28:1908-1912.
FREE FULL TEXT
11. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
12. Robins J, Greenland S, Breslow NE. A general estimator of the variance of the Mantel-Haenszel odds ratio. Am J Epidemiol. 1986;124:719-723.
FREE FULL TEXT
13. DerSimonian R, Laird NM. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
FULL TEXT
|
ISI
| PUBMED
14. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in a meta-analysis. In: Egger M, Davey Smith G, Altman DG, eds. Systematic Reviews in Health Care: Meta-analysis in Context. Annapolis Junction, Md: BMJ Publishing Group; 2001.
15. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
FREE FULL TEXT
16. Albucher JF, Guiraud-Chaumeil B, Chollet F, Cadroy Y, Sie P. Frequency of resistance to activated protein C due to factor V mutation in young patients with ischemic stroke. Stroke. 1996;27:766-767.
17. Bentolila S, Ripoll L, Drouet L, Mazoyer E, Woimant F. Thrombophilia due to 20210 GA prothrombin polymorphism and cerebral ischemia in the young. Stroke. 1997;28:1846-1847.
18. Catto A, Carter A, Ireland H, et al. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol. 1995;15:783-785.
FREE FULL TEXT
19. Chimowitz M, Mansbach H, Schmaier A, Nichols W, Ginsburg D. Factor V mutation and cryptogenic stroke in the young [abstract]. Stroke. 1996;27:188.
20. De Stefano V, Chiusolo P, Paciaroni K, et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood. 1998;91:3562-3565.
FREE FULL TEXT
21. Halbmayer WM, Haushofer A, Angerer V, Finsterer J, Fischer M, Vienna Thrombophilia in Stroke Study Group (VITISS). APC resistance and factor V Leiden (FV:Q506) mutation in patients with ischemic cerebral events. Blood Coagul Fibrinolysis. 1997;8:361-364.
ISI
| PUBMED
22. Hankey GJ, Eikelboom JW, van Bockxmeer FM, Lofthouse E, Staples N, Baker RI. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke. 2001;32:1793-1799.
FREE FULL TEXT
23. Iniesta JA, Corral J, Gonzalez-Conejero R, Rivera J, Vicente V. Prothrombotic genetic risk factors in patients with coexisting migraine and ischemic cerebrovascular disease. Headache. 1999;39:486-489.
FULL TEXT
|
ISI
| PUBMED
24. Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: the Copenhagen City Heart Study and 2 meta-analyses. Blood. 2002;100:3-10.
FREE FULL TEXT
25. Kontula K, Ylikorkala A, Miettinen H, et al. Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost. 1995;73:558-560.
ISI
| PUBMED
26. Lalouschek W, Aull S, Series W, Zeiler K, Mannhalter C. The prothrombin G20210A mutation and factor V Leiden mutation in patients with cerebrovascular disease [letter]. Blood. 1998;92:704-705.
FREE FULL TEXT
27. Landi G, Cella E, Martinelli I, Tagliabue L, Mannucci PM, Zerbi D. Arg506Gln factor V mutation and cerebral ischemia in the young [letter]. Stroke. 1996;27:1697-1698.
28. Lopaciuk S, Bykowska K, Kwiecinski H, et al. Factor V Leiden, prothrombin gene G20210A variant, and methylenetetrahydrofolate reductase C677T genotype in young adults with ischemic stroke. Clin Appl Thromb Hemost. 2001;7:346-350.
29. Madonna P, de Stefano V, Coppola A, et al. Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke. Stroke. 2002;33:51-56.
FREE FULL TEXT
30. Margaglione M, D'Andrea G, Giuliani N, et al. Inherited prothrombotic conditions and premature ischemic stroke: sex difference in the association with factor V Leiden. Arterioscler Thromb Vasc Biol. 1999;19:1751-1756.
FREE FULL TEXT
31. Markus HS, Zhang Y, Jeffery S. Screening for the factor-V Arg 506 Gln mutation in patients with TIA and stroke. Cerebrovasc Dis. 1996;6:360-362.
FULL TEXT
|
ISI
32. Martinelli I, Franchi F, Akwan S, Bettini P, Merati G, Mannucci PM. The transition G to A at position 20210 in the 3'-untranslated region of the prothrombin gene is not associated with cerebral ischemia [letter]. Blood. 1997;90:3806.
FREE FULL TEXT
33. Nabavi DG, Junker R, Wolff E, et al. Prevalence of factor V Leiden mutation in young adults with cerebral ischaemia: a case-control study on 225 patients. J Neurol. 1998;245:653-658.
FULL TEXT
|
ISI
| PUBMED
34. Pezzini A, Del Zotto E, Magoni M, et al. Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale. Stroke. 2003;34:28-33.
FREE FULL TEXT
35. Press RD, Liu XY, Beamer N, Coull BM. Ischemic stroke in the elderly: role of the common factor V mutation causing resistance to activated protein C. Stroke. 1996;27:44-48.
FREE FULL TEXT
36. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912-917.
FREE FULL TEXT
37. Sanchez J, Roman J, de la Torre MJ, Velasco F, Torres A. Low prevalence of the factor V Leiden among patients with ischemic stroke. Haemostasis. 1997;27:9-15.
ISI
| PUBMED
38. Szolnoki Z, Somogyvari F, Kondacs A, Szabo M, Fodor L. Evaluation of the interactions of common genetic mutations in stroke subtypes. J Neurol. 2002;249:1391-1397.
FULL TEXT
|
ISI
| PUBMED
39. van der Bom JG, Bots ML, Haverkate F, et al. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med. 1996;125:265-269.
FREE FULL TEXT
40. Voetsch B, Damasceno BP, Camargo EC, et al. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemost. 2000;83:229-233.
ISI
| PUBMED
41. Zunker P, Hohenstein C, Plendl HJ, et al. Activated protein C resistance and acute ischaemic stroke: relation to stroke causation and age. J Neurol. 2001;248:701-704.
FULL TEXT
|
ISI
| PUBMED
42. Duca F, Sacchi E, Tagliabue L, Tajoli E. C677T methylenetetrahydrofolate reductase (MTHFR) mutation in stroke [abstract]. Thromb Haemost. 1997;78(suppl):102.
43. Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker RI. Association between high homocysteine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke. 2000;31:1069-1075.
FREE FULL TEXT
44. Gross B, Antebi A, Cassel A, Honigman S. Is a mutation in the enzyme MTHFR a risk factor for stroke in young adults [abstract]? Neurology. 2000;54(suppl 3):A142.
45. Harmon DL, Doyle RM, Meleady R, et al. Genetic analysis of the thermolabile variant of 5, 10-methylenetetrahydrofolate reductase as a risk factor for ischemic stroke. Arterioscler Thromb Vasc Biol. 1999;19:208-211.
FREE FULL TEXT
46. Kostulas K, Crisby M, Huang WX, et al. A methylenetetrahydrofolate reductase gene polymorphism in ischaemic stroke and in carotid artery stenosis. Eur J Clin Invest. 1998;28:285-289.
FULL TEXT
|
ISI
| PUBMED
47. Kristensen B, Malm J, Nilsson TK, et al. Hyperhomocysteinemia and hypofibrinolysis in young adults with ischemic stroke. Stroke. 1999;30:974-980.
FREE FULL TEXT
48. Lalouschek W, Aull S, Serles W, et al. Genetic and nongenetic factors influencing plasma homocysteine levels in patients with ischemic cerebrovascular disease and in healthy control subjects. J Lab Clin Med. 1999;133:575-582.
FULL TEXT
|
ISI
| PUBMED
49. Markus HS, Ali N, Swaminathan R, Sankaralingam A, Molloy J, Powell J. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke. 1997;28:1739-1743.
FREE FULL TEXT
50. McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke. 2002;33:2351-2356.
FREE FULL TEXT
51. Pezzini A, Del Zotto E, Archetti S, et al. Plasma homocysteine concentration, C677T MTHFR genotype, and 844ins68bp CBS genotype in young adults with spontaneous cervical artery dissection and atherothrombotic stroke. Stroke. 2002;33:664-669.
FREE FULL TEXT
52. Press RD, Beamer N, Evans A, DeLoughery TG, Coull BM. Role of a common mutation in the homocysteine regulatory enzyme methylenetetrahydrofolate reductase in ischemic stroke. Diagn Mol Pathol. 1999;8:54-58.
FULL TEXT
|
ISI
| PUBMED
53. Reuner KH, Ruf A, Kaps M, Druschky KF, Patscheke H. The mutation C677T in the methylene tetrahydrofolate reductase gene and stroke. Thromb Haemost. 1998;79:450-451.
ISI
| PUBMED
54. Salooja N, Catto A, Carter A, Tudenham EG, Grant PJ. Methylene tetrahydrofolate reductase C677T genotype and stroke. Clin Lab Haematol. 1998;20:357-361.
FULL TEXT
|
ISI
| PUBMED
55. Soriente L, Coppola A, Madonna P, et al. Homozygous C677T mutation of the 5,10 methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in Italian patients with a history of early-onset ischemic stroke. Stroke. 1998;29:869-871.
FREE FULL TEXT
56. Topic E, Timundic AM, Ttefanovic M, et al. Polymorphism of apoprotein E (APOE), methylenetetrahydrofolate reductase (MTHFR) and paraoxonase (PON1) genes in patients with cerebrovascular disease. Clin Chem Lab Med. 2001;39:346-350.
FULL TEXT
|
ISI
| PUBMED
57. Egan RA, Kuyl JM, Press R, Lutsep HL. Lack of prothrombin gene mutation in young stroke patients. J Stroke Cerebrovasc Dis. 2000;9:229-231.
FULL TEXT
58. Gomez Garcia EB, van Goor MP, Leebeek FW, Brouwers GJ, Koudstaal PJ, Dippel DW. Elevated prothrombin is a risk factor for cerebral arterial ischemia in young adults. Clin Neurol Neurosurg. 2002;104:285-288.
FULL TEXT
|
ISI
| PUBMED
59. Halbmayer WM, Haushofer A, Hermann KM, Fischer M. The 20210A allele of the prothrombin gene: a risk factor for juvenile stroke? result of a pilot study [letter]. Blood Coagul Fibrinolysis. 1998;9:209-210.
ISI
| PUBMED
60. Lichy C, Reuner KH, Buggle F, et al. Prothrombin g20210a mutation, but not factor V Leiden, is a risk factor in patients with cerebral ischemia associated with persistent foramen ovale. Paper presented at: 16th International Congress on Fibrinolysis and Proteolysis in conjunction with the 17th International Fibrinogen Workshop; September 8-13, 2002; Munich, Germany.
61. Reuner KH, Ruf A, Grau A, et al. Prothrombin gene G20210A transition is a risk factor for cerebral venous thrombosis. Stroke. 1998;29:1765-1769.
FREE FULL TEXT
62. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation. 1999;99:999-1004.
FREE FULL TEXT
63. Smiles AM, Jenny NS, Tang Z, Arnold A, Cushman M, Tracy RP. No association of plasma prothrombin concentration or the G20210A mutation with incident cardiovascular disease: results from the Cardiovascular Health Study. Thromb Haemost. 2002;87:614-621.
ISI
| PUBMED
64. Agerholm-Larsen B, Tybjaerg-Hansen A, Frikke-Schmidt R, Gronholdt ML, Jensen G, Nordestgaard BG. ACE gene polymorphism as a risk factor for ischemic cerebrovascular disease. Ann Intern Med. 1997;127:346-355.
FREE FULL TEXT
65. Catto A, Carter AM, Barrett JH, et al. Angiotensin-converting enzyme insertion/deletion polymorphism and cerebrovascular disease. Stroke. 1996;27:435-440.
FREE FULL TEXT
66. Kostulas K, Huang WX, Crisby M, et al. An angiotensin-converting enzyme gene polymorphism suggests a genetic distinction between ischaemic stroke and carotid stenosis. Eur J Clin Invest. 1999;29:478-483.
FULL TEXT
|
ISI
| PUBMED
67. Margaglione M, Celentano E, Grandone E, et al. Deletion polymorphism in the angiotensin-converting enzyme gene in patients with a history of ischemic stroke. Arterioscler Thromb Vasc Biol. 1996;16:304-309.
FREE FULL TEXT
68. Markus HS, Barley J, Lunt R, et al. Angiotensin-converting enzyme gene deletion polymorphism: a new risk factor for lacunar stroke but not carotid atheroma. Stroke. 1995;26:1329-1333.
FREE FULL TEXT
69. Peterlin B, Petrovic D, Zorc M, Keber I. Deletion/insertion polymorphism in the angiotension-converting enzyme gene as a risk factor in the Slovenian patients with coronary heart disease. Pflugers Arch. 2000;439(suppl):R40-R41.
FULL TEXT
|
ISI
| PUBMED
70. Pfohl M, Fetter M, Koch M, Barth CM, Rudiger W, Haring HU. Association between angiotensin I–converting enzyme genotypes, extracranial artery stenosis, and stroke. Atherosclerosis. 1998;140:161-166.
FULL TEXT
|
ISI
| PUBMED
71. Sharma P, Carter ND, Barley J, Brown MM. Molecular approach to assessing the genetic risk of cerebral infarction: deletion polymorphism in the gene encoding angiotensin 1–converting enzyme. J Hum Hypertens. 1994;8:645-648.
ISI
| PUBMED
72. Ueda S, Weir CJ, Inglis GC, Murray GD, Muir KW, Lees KR. Lack of association between angiotensin converting enzyme gene insertion/deletion polymorphism and stroke. J Hypertens. 1995;13:1597-1601.
ISI
| PUBMED
73. Zee RY, Ridker PM, Stampfer MJ, Hennekens CH, Lindpaintner K. Prospective evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of stroke. Circulation. 1999;99:340-343.
FREE FULL TEXT
74. Catto AJ, Kohler HP, Bannan S, Stickland M, Carter A, Grant PJ. Factor XIII Val 34 Leu: a novel association with primary intracerebral hemorrhage. Stroke. 1998;29:813-816.
FREE FULL TEXT
75. Corral J, Gonzalez-Conejero R, Iniesta JA, Rivera J, Martinez C, Vicente V. The FXIII Val34Leu polymorphism in venous and arterial thromboembolism. Haematologica. 2000;85:293-297.
FREE FULL TEXT
76. Elbaz A, Poirier O, Canaple S, Chedru F, Cambien F, Amarenco P. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood. 2000;95:586-591.
FREE FULL TEXT
77. Endler G, Funk M, Haering D, et al. Is the factor XIII 34Val/Leu polymorphism a protective factor for cerebrovascular disease? Br J Haematol. 2003;120:310-314.
FULL TEXT
|
ISI
| PUBMED
78. Gemmati D, Serino ML, Ongaro A, et al. A common mutation in the gene for coagulation factor XIII-A (VAL34Leu): a risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases. Am J Hematol. 2001;67:183-188.
FULL TEXT
|
ISI
| PUBMED
79. Reiner AP, Frank MB, Schwartz SM, et al. Coagulation factor XIII polymorphisms and the risk of myocardial infarction and ischaemic stroke in young women. Br J Haematol. 2002;116:376-382.
FULL TEXT
|
ISI
| PUBMED
80. Basun H, Corder EH, Guo Z, et al. Apolipoprotein E polymorphism and stroke in a population sample aged 75 years or more. Stroke. 1996;27:1310-1315.
FREE FULL TEXT
81. Catto AJ, McCormack LJ, Mansfield MW, et al. Apolipoprotein E polymorphism in cerebrovascular disease. Acta Neurol Scand. 2000;101:399-404.
FULL TEXT
|
ISI
| PUBMED
82. Couderc R, Mahieux F, Bailleul S, Fenelon G, Mary R, Fermanian J. Prevalence of apolipoprotein E phenotypes in ischemic cerebrovascular disease: a case-control study. Stroke. 1993;24:661-664.
FREE FULL TEXT
83. Frikke-Schmidt R, Nordestgaard BG, Thudium D, Moes Gronholdt ML, Tybjaerg-Hansen A. APOE genotype predicts AD and other dementia but not ischemic cerebrovascular disease. Neurology. 2001;56:194-200.
FREE FULL TEXT
84. Hachinski V, Graffagnino C, Beaudry M, et al. Lipids and stroke: a paradox resolved. Arch Neurol. 1996;53:303-308.
FREE FULL TEXT
85. Kessler C, Spitzer C, Stauske D, et al. The apolipoprotein E and  -fibrinogen G/A-455 gene polymorphisms are associated with ischemic stroke involving large-vessel disease. Arterioscler Thromb Vasc Biol. 1997;17:2880-2884.
FREE FULL TEXT
86. MacLeod MJ, De Lange RP, Breen G, Meiklejohn D, Lemmon H, Clair DS. Lack of association between apolipoprotein E genotype and ischaemic stroke in a Scottish population. Eur J Clin Invest. 2001;31:570-573.
FULL TEXT
|
ISI
| PUBMED
87. Margaglione M, Seripa D, Gravina C, et al. Prevalence of apolipoprotein E alleles in healthy subjects and survivors of ischemic stroke: an Italian Case-Control Study. Stroke. 1998;29:399-403.
FREE FULL TEXT
88. Carlsson LE, Greinacher A, Spitzer C, Walther R, Kessler C. Polymorphisms of the human platelet antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the platelet receptors for fibrinogen (GPIIb/IIIa), von Willebrand factor (GPIb/IX), and collagen (GPIa/IIa) are not correlated with an increased risk for stroke. Stroke. 1997;28:1392-1395.
FREE FULL TEXT
89. Carter AM, Catto AJ, Bamford JM, Grant PJ. Association of the platelet glycoprotein IIb HPA-3 polymorphism with survival after acute ischemic stroke. Stroke. 1999;30:2606-2611.
FREE FULL TEXT
90. Kekomaki S, Hamalainen L, Kauppinen-Makelin R, Palomaki H, Kaste M, Kontula K. Genetic polymorphism of platelet glycoprotein IIIa in patients with acute myocardial infarction and acute ischaemic stroke. J Cardiovasc Risk. 1999;6:13-17.
ISI
| PUBMED
91. Reiner AP, Kumar PN, Schwartz SM, et al. Genetic variants of platelet glycoprotein receptors and risk of stroke in young women. Stroke. 2000;31:1628-1633.
FREE FULL TEXT
92. Reuner KH, Elgas M, Kaps M, Ruf A, Patscheke H. The human platelet antigen HPA-1a/1b (PI(A1)/PI(A2)) polymorphism and cerebral ischaemia [letter]. Thromb Haemost. 1997;78:964-965.
ISI
| PUBMED
93. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet. 1997;349:385-388.
FULL TEXT
|
ISI
| PUBMED
94. van Goor ML, Gomez Garcia E, Brouwers GJ, Leebeek FW, Koudstaal PJ, Dippel DW. PLA1/A2 polymorphism of the platelet glycoprotein receptor IIb/IIIa in young patients with cryptogenic TIA or ischemic stroke. Thromb Res. 2002;108:63-65.
FULL TEXT
|
ISI
| PUBMED
95. Wagner KR, Giles WH, Johnson CJ, et al. Platelet glycoprotein receptor IIIa polymorphism P1A2 and ischemic stroke risk: the Stroke Prevention in Young Women Study. Stroke. 1998;29:581-585.
FREE FULL TEXT
96. Elbaz A, Poirier O, Moulin T, et al. Association between the Glu298Asp polymorphism in the endothelial constitutive nitric oxide synthase gene and brain infarction. Stroke. 2000;31:1634-1639.
FREE FULL TEXT
97. MacLeod MJ, Dahiyat MT, Cumming A, Meiklejohn D, Shaw D, St Clair D. No association between Glu/Asp polymorphism of NOS3 gene and ischemic stroke. Neurology. 1999;53:418-420.
FREE FULL TEXT
98. Markus HS, Ruigrok Y, Ali N, Powell JF. Endothelial nitric oxide synthase exon 7 polymorphism, ischemic cerebrovascular disease, and carotid atheroma. Stroke. 1998;29:1908-1911.
FREE FULL TEXT
99. Endler G, Lalouschek W, Exner M, Mitterbauer G, Haring D, Mannhalter C. The 4G/4G genotype at nucleotide position –675 in the promotor region of the plasminogen activator inhibitor 1 (PAI–1) gene is less frequent in young patients with minor stroke than in controls. Br J Haematol. 2000;110:469-471.
FULL TEXT
|
ISI
| PUBMED
100. Hindorff LA, Schwartz SM, Siscovick DS, Psaty BM, Longstreth WT Jr, Reiner AP. The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk. 2002;9:131-137.
FULL TEXT
|
ISI
| PUBMED
101. Roest M, van der Schouw YT, Banga JD, et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation. 2000;101:67-70.
FREE FULL TEXT
102. Baker RI, Eikelboom J, Lofthouse E, et al. Platelet glycoprotein Ib Kozak polymorphism is associated with an increased risk of ischemic stroke. Blood. 2001;98:36-40.
FREE FULL TEXT
103. Carter AM, Catto AJ, Bamford JM, Grant PJ. Platelet GP IIIa PlA and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. Arterioscler Thromb Vasc Biol. 1998;18:1124-1131.
FREE FULL TEXT
104. Gonzalez-Conejero R, Lozano ML, Rivera J, et al. Polymorphisms of platelet membrane glycoprotein Ib associated with arterial thrombotic disease. Blood. 1998;92:2771-2776.
FREE FULL TEXT
105. Corral J, Gonzalez-Conejero R, Lozano ML, Rivera J, Vicente V. Genetic polymorphisms of factor VII are not associated with arterial thrombosis. Blood Coagul Fibrinolysis. 1998;9:267-272.
ISI
| PUBMED
106. Heywood DM, Carter AM, Catto AJ, Bamford JM, Grant PJ. Polymorphisms of the factor VII gene and circulating FVII:C levels in relation to acute cerebrovascular disease and poststroke mortality. Stroke. 1997;28:816-821.
FREE FULL TEXT
107. Corral J, Lozano ML, Gonzalez-Conejero R, et al. A common polymorphism flanking the ATG initiator codon of GPIb does not affect expression and is not a major risk factor for arterial thrombosis. Thromb Haemost. 2000;83:23-28.
ISI
| PUBMED
108. Frank MB, Reiner AP, Schwartz SM, et al. The Kozak sequence polymorphism of platelet glycoprotein Ib and risk of nonfatal myocardial infarction and nonfatal stroke in young women. Blood. 2001;97:875-879.
FREE FULL TEXT
109. Huang P, Kostulas K, Huang WX, Crisby M, Kostulas V, Hillert J. Lipoprotein lipase gene polymorphisms in ischaemic stroke and carotid stenosis. Eur J Clin Invest. 1997;27:740-742.
FULL TEXT
|
ISI
| PUBMED
110. Myllykangas L, Polvikoski T, Sulkava R, et al. Association of lipoprotein lipase Ser447Ter polymorphism with brain infarction: a population-based neuropathological study. Ann Med. 2001;33:486-492.
ISI
| PUBMED
111. Wittrup HH, Nordestgaard BG, Sillesen H, Schnohr P, Tybjaerg-Hansen A. A common mutation in lipoprotein lipase confers a 2-fold increase in risk of ischemic cerebrovascular disease in women but not in men. Circulation. 2000;101:2393-2397.
FREE FULL TEXT
112. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1202-1206.
FREE FULL TEXT
113. Keavney B, McKenzie C, Parish S, et al, International Studies of Infarct Survival (ISIS) Collaborators. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. Lancet. 2000;355:434-442.
ISI
| PUBMED
114. Keavney B, Parish S, Palmer A, et al. Large-scale evidence that the cardiotoxicity of smoking is not significantly modified by the apolipoprotein E 2/3/4 genotype. Lancet. 2003;361:396-398.
FULL TEXT
|
ISI
| PUBMED
115. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
FULL TEXT
| PUBMED
116. Dahlback B. New molecular insights into the genetics of thrombophilia: resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost. 1995;74:139-148.
ISI
| PUBMED
117. Franco RF, Trip MD, ten Cate H, et al. the 20210 GA mutation in the 3'-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. Br J Haematol. 1999;104:50-54.
FULL TEXT
|
ISI
| PUBMED
118. Cattaneo M, Chantarangkul V, Taioli E, Santos JH, Tagliabue L. The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels. Thromb Res. 1999;93:1-8.
FULL TEXT
|
ISI
| PUBMED
119. Tiret L, Rigat B, Visvikis S, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I–converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet. 1992;51:197-205.
ISI
| PUBMED
120. Sharma P, Carter ND, Barley J, Lunt R, Seymour CA, Brown MM. Polymorphisms in the gene encoding angiotensin 1–converting enzyme and relationship to its post-translational product in cerebral infarction. J Hum Hypertens. 1994;8:633-634.
ISI
| PUBMED
121. Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A. ACE gene polymorphism in cardiovascular disease: meta-analyses of small and large studies in whites. Arterioscler Thromb Vasc Biol. 2000;20:484-492.
FREE FULL TEXT
122. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II–mediated cardiovascular and renal diseases. Pharmacol Rev. 2000;52:11-34.
FREE FULL TEXT
123. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
FULL TEXT
|
ISI
| PUBMED
124. Klerk M, Verhoef P, Clarke R, et al, MTHFR Studies Collaboration Group. MTHFR 677CT polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288:2023-2031.
FREE FULL TEXT
125. Lellouche F, Dorval I, Dewilde J, Van Walleghem E. Presence of G1691A mutation on the gene of factor V in arterial thrombosis [letter] [in French]. Presse Med. 1995;24:869.
126. Moliaka IuK, Petruk SV, Kir’ianov SA, et al. Association analysis of polymorphism in angiotensin-converting enzyme gene in ischemic stroke [in Russian]. Zh Nevrol Psikhiatr Im S S Korsakova. 1998;98:35-37.
PUBMED
127. Pongracz E, Tordai A, Csornai M, Nagy Z. Genetics of blood coagulation in young stroke patients [in Hungarian]. Ideggyogy Sz. 2002;55:111-117.
PUBMED
128. Pongracz E, Tordai A, Csornai M, Nagy Z. Investigation of insertion/deletion polymorphism of the ACE gene in stroke patients [in Hungarian]. Ideggyogy Sz. 2002;55:157-163.
PUBMED
129. Pongracz E, Tordai A, Csornai M, Nagy Z. Platelet glycoprotein IIb/IIIa (LeuPro 33) polymorphism in stroke patients [in Hungarian]. Orv Hetil. 2001;142:781-785.
PUBMED
130. Yang Q, Khoury MJ, Botto L, et al. Improving the prediction of complex diseases by testing for multiple disease-susceptibility genes. Am J Hum Genet. 2003;72:636-649.
FULL TEXT
|
ISI
| PUBMED
131. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet. 2003;361:865-872.
FULL TEXT
|
ISI
| PUBMED
SECTION EDITOR: DAVID E. PLEASURE, MD
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Candidate Gene Polymorphisms for Ischemic Stroke
Matarin et al.
Stroke 2009;40:3436-3442.
ABSTRACT
| FULL TEXT
Relation of Candidate Genes that Encode for Endothelial Function to Migraine and Stroke: The Stroke Prevention in Young Women Study
MacClellan et al.
Stroke 2009;40:e550-e557.
ABSTRACT
| FULL TEXT
Common genetic markers and prediction of recurrent events after ischemic stroke in young adults
Pezzini et al.
Neurology 2009;73:717-723.
ABSTRACT
| FULL TEXT
Whole Genome Approaches in Ischemic Stroke
Meschia
Stroke 2009;40:S61-S63.
ABSTRACT
| FULL TEXT
ACE D/I polymorphism, migraine, and cardiovascular disease in women
Schurks et al.
Neurology 2009;72:650-656.
ABSTRACT
| FULL TEXT
Polymorphisms in Inflammatory Genes and the Risk of Ischemic Stroke and Transient Ischemic Attack: Results of a Multilocus Genotyping Assay
Greisenegger et al.
Clin. Chem. 2009;55:134-138.
ABSTRACT
| FULL TEXT
Use of Intravenous Tissue Plasminogen Activator in a 16-Year-Old Patient with Basilar Occlusion
Heil et al.
J Child Neurol 2008;23:1049-1053.
ABSTRACT
Variation in the PDE4D Gene and Ischemic Stroke Risk: A Systematic Review and Meta-analysis on 5200 Cases and 6600 Controls
Bevan et al.
Stroke 2008;39:1966-1971.
ABSTRACT
| FULL TEXT
Polymorphisms in Platelet Glycoprotein 1b{alpha} and Factor VII and Risk of Ischemic Stroke: A Meta-Analysis
Maguire et al.
Stroke 2008;39:1710-1716.
ABSTRACT
| FULL TEXT
Association Between Apolipoprotein E Genotype and Carotid Intima-Media Thickness May Suggest a Specific Effect on Large Artery Atherothrombotic Stroke
Paternoster et al.
Stroke 2008;39:48-54.
ABSTRACT
| FULL TEXT
Relevance of Genetics and Genomics for Prevention and Treatment of Cardiovascular Disease: A Scientific Statement From the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group
Arnett et al.
Circulation 2007;115:2878-2901.
ABSTRACT
| FULL TEXT
Candidate Genetic Risk Factors of Stroke: Results of a Multilocus Genotyping Assay
Lalouschek et al.
Clin. Chem. 2007;53:600-605.
ABSTRACT
| FULL TEXT
Effects of apolipoprotein E genotype on outcome after ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage
Martinez-Gonzalez and Sudlow
J. Neurol. Neurosurg. Psychiatry 2006;77:1329-1335.
ABSTRACT
| FULL TEXT
Endothelial Nitric Oxide Synthase Gene Polymorphisms and Cardiovascular Disease: A HuGE Review
Casas et al.
Am J Epidemiol 2006;164:921-935.
ABSTRACT
| FULL TEXT
MTHFR 677TT genotype increases the risk for cervical artery dissections.
Kloss et al.
J. Neurol. Neurosurg. Psychiatry 2006;77:951-952.
ABSTRACT
| FULL TEXT
Potential New Risk Factors for Ischemic Stroke: What Is Their Potential?
Hankey
Stroke 2006;37:2181-2188.
ABSTRACT
| FULL TEXT
Familial Risk of Ischemic and Hemorrhagic Stroke: A Large-Scale Study of the Swedish Population
Sundquist et al.
Stroke 2006;37:1668-1673.
ABSTRACT
| FULL TEXT
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline.
Sacco et al.
Circulation 2006;113:e409-e449.
ABSTRACT
| FULL TEXT
The Siblings With Ischemic Stroke Study (SWISS): A Progress Report.
Meschia et al.
Clin Med Res 2006;4:12-21.
ABSTRACT
| FULL TEXT
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline.
Sacco et al.
Stroke 2006;37:577-617.
ABSTRACT
| FULL TEXT
Does Apolipoprotein E Genotype Influence the Risk of Ischemic Stroke, Intracerebral Hemorrhage, or Subarachnoid Hemorrhage?: Systematic Review and Meta-Analyses of 31 Studies Among 5961 Cases and 17 965 Controls
Sudlow et al.
Stroke 2006;37:364-370.
ABSTRACT
| FULL TEXT
Genetics of Vascular Cognitive Impairment: The Opportunity and the Challenges
Leblanc et al.
Stroke 2006;37:248-255.
ABSTRACT
| FULL TEXT
Apolipoprotein E Genotype and Incident Ischemic Stroke: The Atherosclerosis Risk in Communities Study
Sturgeon et al.
Stroke 2005;36:2484-2486.
ABSTRACT
| FULL TEXT
Teaching NeuroImage: Thromboembolic stroke in ICA stenosis
Isenmann et al.
Neurology 2005;65:E16-E16.
FULL TEXT
Influence of Cytochrome P450 2C9*2 and 2C9*3 Variants on the Risk of Ischemic Stroke: A Cross-sectional Case-Control Study
Funk et al.
Clin. Chem. 2005;51:1716-1718.
FULL TEXT
Genetic Association Studies in Stroke: Methodological Issues and Proposed Standard Criteria
Dichgans and Markus
Stroke 2005;36:2027-2031.
ABSTRACT
| FULL TEXT
Associations of the Angiotensin II Type 1 Receptor A1166C and the Endothelial NO Synthase G894T Gene Polymorphisms With Silent Subcortical White Matter Lesions in Essential Hypertension
Henskens et al.
Stroke 2005;36:1869-1873.
ABSTRACT
| FULL TEXT
Plasminogen Activator Inhibitor-1 4G/5G Polymorphism and Risk of Stroke: Replicated Findings in Two Nested Case-Control Studies Based on Independent Cohorts
Wiklund et al.
Stroke 2005;36:1661-1665.
ABSTRACT
| FULL TEXT
Update on the Genetics of Stroke and Cerebrovascular Disease 2004
Alberts and Tournier-Lasserve
Stroke 2005;36:179-181.
FULL TEXT
|
